Cord Blood

Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.

Anja Health Makes Cord Blood, Cord Tissue and Placenta Banking an Employee Benefit and Invites Other Employers to Join In

September 15, 2026 By BioInformant Team Leave a Comment

Anja Health is offering stem cell banking as an employee benefit and inviting employers to bring cord blood, cord tissue and placenta banking to their teams.

LOS ANGELES , CA, UNITED STATES, September 7, 2026 – Welcoming a baby is one of life’s most important moments. Anja Health believes employers have an opportunity to make that moment even more meaningful.

Anja Health announced today that it is providing cord blood, cord tissue and placenta banking as an employee benefit for eligible employees who are expecting a child. The company is also inviting other employers to consider offering the same type of benefit to their employees. [Read more…]

Cryopraxis, BioNK and Radboudumc Partner to Transfer Cord Blood-Derived NK Cell Technology to Brazil

September 13, 2026 By BioInformant Team Leave a Comment

Agreement establishes a phased technology-transfer program for the RNK001/HSPC-NK platform and creates a framework for future CAR-NK development

SÃO PAULO, Brazil and NIJMEGEN, the Netherlands — September 2026 — Cryopraxis, BioNK and Radboud university medical center (Radboudumc) have entered into a collaboration agreement to transfer and establish in Brazil technology for the manufacture of allogeneic Natural Killer (NK) cells derived from umbilical cord blood hematopoietic stem and progenitor cells. [Read more…]

Cord Blood Industry Consolidation Escalates in 2026

September 12, 2026 By Cade Hildreth, Founder & President 2 Comments

The global cord blood industry experienced strong growth from the early 1990’s through the late 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space.

Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation, cutting the global number of cord blood banks by approximately half.

Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, Asia, and Latin America. [Read more…]

Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance

July 11, 2026 By BioInformant Team Leave a Comment

CRANBURY, N.J. and SUZHOU, China, July 8, 2026 — Recently, Porton Advanced proudly announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome manufacturing has been accepted for filing by the FDA’s Center for Biologics Evaluation and Research (CBER), under Drug Master File (DMF) #32973.

This milestone further strengthens Porton Advanced’s position in the rapidly evolving exosome therapeutics market. With the DMF filing, sponsors advancing exosome programs can reference DMF #32973 in their own regulatory submissions, significantly accelerating U.S. FDA review pathways and reducing duplicative documentation. [Read more…]

MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis

July 5, 2026 By BioInformant Team Leave a Comment

U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects

CAMBRIDGE, Mass.–MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today the treatment of the first U.S. participant in its Phase III clinical trial evaluating its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in adults with knee osteoarthritis. The FDA has agreed that this single pivotal study, supported by confirmatory evidence from prior Phase 3 trials in South Korea and Japan together with Korean real-world evidence, can serve as the basis for MEDIPOST’s planned U.S. BLA filing. The milestone marks a significant step forward in MEDIPOST’s mission to bring a first-of-its-kind regenerative therapy to patients in the United States. This procedure was performed by Dr. Justin Newman at Orthopedic Centers of Colorado. [Read more…]